+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Narcolepsy Drugs Market by Disease and Therapeutic Type: Global Opportunity Analysis and Industry Forecast, 2021-2030

  • PDF Icon

    Report

  • 198 Pages
  • September 2021
  • Region: Global
  • Allied Market Research
  • ID: 5480768
The narcolepsy drugs market was valued at $2,680.06 million in 2020, and is projected to reach $6,667.80 million by 2030, registering a CAGR of 9.6% from 2021 to 2030. Narcolepsy is mainly a long-term neurological disorder characterized by a classic tetrad of excessive daytime sleepiness with irresistible sleep attacks, cataplexy (sudden bilateral loss of muscle tone), hypnagogic hallucination, and sleep paralysis. Around 70% individuals experience episodes of sudden loss of muscle strength, this is often referred to as cataplexy, which can be brought on by strong emotions. Less commonly, there may be inability to move or vivid hallucinations when falling asleep or waking up. People with narcolepsy tend to sleep about the same number of hours per day as people without, but the quality of sleep tends to be worse.





Narcolepsy is a rare and under-diagnosed chronic condition affecting both males and females equally. The severity of the disease and rise in number of individuals being affected by narcolepsy are the factors that drive the market growth. Furthermore, the availability of reimbursement process for FDA-approved prescription medicines help increase the demand for these drugs. However, lack of awareness regarding the diagnosis and treatment availability is predicted to hinder the market growth. There is an increase in the number of programs organized by various organizations mainly due to surge in awareness, which is anticipated to provide lucrative opportunities for the market growth.

The narcolepsy drugs market is segmented on the basis of disease type, therapeutics type, and region. By disease type, the market is classified into daytime extreme sleepiness, cataplexia, and other disease type. By therapeutics type, the market is divided into central nervous system stimulants, tricyclic antidepressants, sodium oxybate, selective serotonin reuptake inhibitor, and other therapeutic type. By region, the global narcolepsy drugs market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

This report provides comprehensive competitive analysis and profiles of prominent market players such Arena Pharmaceuticals, Inc., Bioprojet Company, Graymark Healthcare, Inc., Hikma Pharmaceuticals PLC, Jazz Pharmaceuticals plc, Ligand Pharmaceuticals Incorporated, Shionogi Inc., Takeda Pharmaceutical Company Limited, Novartis International AG, and Teva Pharmaceutical Industries Limited.

KEY BENEFITS FOR STAKEHOLDERS


  • The study provides an in-depth analysis of the global Narcolepsy drugs market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
  • Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the key segments of the industry helps to understand the products and end users of Narcolepsy drugs used across the globe.
  • Key market players and their strategies have been analysed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS


By Disease Type

  • Daytime Extreme Sleepiness
  • Cataplexia
  • Others Disease Type

By Therapeutic Type

Central Nervous System Stimulants
Tricyclic Antidepressants
Sodium Oxybate
Selective Serotonin Reuptake Inhibitor
Others Therapeutic Type

By Region


North America
  • U.S.
  • Canada
  • Mexico

Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • Rest of Asia-Pacific

LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

KEY MARKET PLAYERS

  • Arena Pharmaceuticals, Inc.
  • Bioprojet Company
  • Graymark Healthcare, Inc.
  • Hikma Pharmaceuticals PLC
  • Jazz Pharmaceuticals plc
  • Ligand Pharmaceuticals Incorporated
  • Shionogi Inc.
  • Takeda Pharmaceutical Company Limited
  • Novartis International AG
  • Teva Pharmaceutical Industries Limited
Frequently Asked Questions about the Narcolepsy Drugs Market

What is the estimated value of the Narcolepsy Drugs Market?

The Narcolepsy Drugs Market was estimated to be valued at $2680.06 million in 2020.

What is the growth rate of the Narcolepsy Drugs Market?

The growth rate of the Narcolepsy Drugs Market is 9.5%, with an estimated value of $6667.8 million by 2030.

What is the forecasted size of the Narcolepsy Drugs Market?

The Narcolepsy Drugs Market is estimated to be worth $6667.8 million by 2030.

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers, restraints, and opportunity
3.5.2. Drivers
3.5.2.1. Increase in global prevalence of narcolepsy
3.5.2.2. Narcolepsy awareness programs and services
3.5.2.3. Presence of reimbursement policies regarding narcolepsy
3.5.3. Restraints
3.5.3.1. Adverse effects and risks related to narcolepsy drugs
3.5.3.2. Delayed diagnosis or misdiagnosis
3.5.4. Opportunity
3.5.4.1. Untapped markets in the developing countries
3.6. Impact of COVID-19 on the NARCOLEPSY DRUG market
3.6.1. Overview
3.6.2. Impact analysis
CHAPTER 4: NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Daytime extreme sleepiness
4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Cataplexia
4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Other disease type
4.4.1. Key market trends and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
CHAPTER 5: NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Central nervous system stimulants
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Tricyclic antidepressants
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Sodium oxybate
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.5. Selective serotonin reuptake inhibitor
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country
5.6. Other therapeutic type
5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by country
CHAPTER 6: NARCOLEPSY DRUGS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key opportunities and forecast
6.2.2. Market size and forecast, disease type
6.2.3. Market size and forecast, by therapeutic type
6.2.4. Market size and forecast, by country
6.2.4.1. U. S.
6.2.4.1.1. U. S. market size and forecast, by disease type
6.2.4.1.2. U. S. market size and forecast, by therapeutic type
6.2.4.2. Canada
6.2.4.2.1. Canada market size and forecast, by disease type
6.2.4.2.2. Canada market size and forecast, by therapeutic type
6.2.4.3. Mexico
6.2.4.3.1. Mexico market size and forecast, by disease type
6.2.4.3.2. Mexico market size and forecast, by therapeutic type
6.3. Europe
6.3.1. Key opportunities and forecast
6.3.2. Market size and forecast, by disease type
6.3.3. Market size and forecast, by therapeutic type
6.3.4. Market size and forecast, by country
6.3.4.1. Germany
6.3.4.1.1. Germany market size and forecast, by disease type
6.3.4.1.2. Germany market size and forecast, by therapeutic type
6.3.4.2. France
6.3.4.2.1. France market size and forecast, by disease type
6.3.4.2.2. France market size and forecast, by therapeutic type
6.3.4.3. UK
6.3.4.3.1. UK market size and forecast, by disease type
6.3.4.3.2. UK market size and forecast, by therapeutic type
6.3.4.4. Italy
6.3.4.4.1. Italy market size and forecast, by disease type
6.3.4.4.2. Italy market size and forecast, by therapeutic type
6.3.4.5. Spain
6.3.4.5.1. Spain market size and forecast, by disease type
6.3.4.5.2. Spain market size and forecast, by therapeutic type
6.3.4.6. Rest of Europe
6.3.4.6.1. Rest of Europe market size and forecast, by disease type
6.3.4.6.2. Rest of Europe market size and forecast, by therapeutic type
6.4. Asia-Pacific
6.4.1. Key opportunities and forecast
6.4.2. Market size and forecast, by disease type
6.4.3. Market size and forecast, therapeutic type
6.4.4. Market size and forecast, by country
6.4.4.1. Japan
6.4.4.1.1. Japan market size and forecast, by disease type
6.4.4.1.2. Japan market size and forecast, by therapeutic type
6.4.4.2. China
6.4.4.2.1. China market size and forecast, by disease type
6.4.4.2.2. China market size and forecast, by therapeutic type
6.4.4.3. Australia
6.4.4.3.1. Australia market size and forecast, by disease type
6.4.4.3.2. Australia market size and forecast, by therapeutic type
6.4.4.4. India
6.4.4.4.1. India market size and forecast, by disease type
6.4.4.4.2. India market size and forecast, by therapeutic type
6.4.4.5. South Korea
6.4.4.5.1. South Korea market size and forecast, by disease type
6.4.4.5.2. South Korea market size and forecast, by therapeutic type
6.4.4.6. Rest of Asia-Pacific
6.4.4.6.1. Rest of Asia-Pacific market size and forecast, by disease type
6.4.4.6.2. Rest of Asia-Pacific market size and forecast, by therapeutic type
6.5. LAMEA
6.5.1. Key opportunities and forecast
6.5.2. Market size and forecast, by disease type
6.5.3. Market size and forecast, by therapeutic type
6.5.4. Market size and forecast, by country
6.5.4.1. Brazil
6.5.4.1.1. Brazil market size and forecast, by disease type
6.5.4.1.2. Brazil market size and forecast, by therapeutic type
6.5.4.2. Saudi Arabia
6.5.4.2.1. Saudi Arabia market size and forecast, by disease type
6.5.4.2.2. Saudi Arabia market size and forecast, by therapeutic type
6.5.4.3. South Africa
6.5.4.3.1. South Africa market size and forecast, by disease type
6.5.4.3.2. South Africa market size and forecast, by therapeutic
6.5.4.4. Rest of LAMEA
6.5.4.4.1. Rest of LAMEA market size and forecast, by disease
6.5.4.4.2. Rest of LAMEA market size and forecast, by therapeutics
CHAPTER 7: COMPANY PROFILES153
7.1. Arena Pharmaceuticals, Inc.
7.1.1. Company overview
7.1.2. Operating business segments
7.1.3. Product portfolio
7.1.4. Business performance
7.2. BIOPROJET COMPANY
7.2.1. Company overview
7.2.2. Operating business segments
7.2.3. Product portfolio
7.3. GRAYMARK HEALTHCARE, INC.
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.4. Hikma Pharmaceuticals Plc
7.4.1. Company overview
7.4.2. Operating business segments
7.4.3. Product portfolio
7.4.4. Business performance
7.4.5. Key strategic moves and developments
7.5. JAZZ PHARMACEUTICALS PLC
7.5.1. Company overview
7.5.2. Operating business segments
7.5.3. Product portfolio
7.5.4. Business performance
7.5.5. Key strategic moves and developments
7.6. LIGAND PHARMACEUTICALS, INC.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments
7.7. Shionogi Inc.
7.7.1. Company overview
7.7.2. Operating business segments
7.7.3. Product portfolio
7.7.4. Business performance
7.8. Takeda Pharmaceutical Company Limited
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.9. NOVARTIS INTERNATIONAL AG
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.10. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
7.10.1. Company overvie
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
List of Tables
TABLE 01. GLOBAL NARCOLEPSY DRUGS MARKET REVENUE, BY DISEASE, 2020-2030 ($MILLION)
TABLE 02. NARCOLEPSY DRUGS MARKET FOR DAYTIME EXTREME SLEEPINESS, BY REGION, 2020-2030 ($MILLION)
TABLE 03. NARCOLEPSY DRUGS MARKET FOR CATAPLEXIA, BY REGION, BY REGION, 2020-2030 ($MILLION)
TABLE 04. NARCOLEPSY DRUGS MARKET FOR OTHER DISEASE TYPE, BY REGION, 2020-2030 ($MILLION)
TABLE 05. GLOBAL NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020-2030 ($MILLION)
TABLE 06. NARCOLEPSY DRUGS MARKET FOR CENTRAL NERVOUS SYSTEM STIMULANTS, BY REGION, 2020-2030 ($MILLION)
TABLE 07. NARCOLEPSY DRUGS MARKET FOR TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2020-2030 ($MILLION)
TABLE 08. SODIUM OXYBATE FOR NARCOLEPSY DRUGS MARKET REVENUE, BY REGION, 2020-2030 ($MILLION)
TABLE 09. NARCOLEPSY DRUGS MARKET FOR SELECTIVE SEROTONIN REUPTAKE INHIBITOR, BY REGION, 2020-2030 ($MILLION)
TABLE 10. NARCOLEPSY DRUGS MARKET FOR OTHER THERAPEUTIC TYPE, BY REGION, 2020-2030 ($MILLION)
TABLE 11. NARCOLEPSY DRUGS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 12. NORTH AMERICA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 13. NORTH AMERICA NARCOLEPSY DRUG MARKET, THERAPEUTIC TYPE, 2020-2030 ($MILLION)
TABLE 14. NORTH AMERICA NARCOLEPSY DRUGS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 15. U.S. NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 16. U.S. NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020-2030 ($MILLION)
TABLE 17. CANADA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 18. CANADA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020-2030 ($MILLION)
TABLE 19. MEXICO NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 20. MEXICO NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020-2030 ($MILLION)
TABLE 21. EUROPE NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 22. EUROPE NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020-2030 ($MILLION)
TABLE 23. EUROPE NARCOLEPSY DRUGS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 24. GERMANY NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 25. GERMANY NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020-2030 ($MILLION)
TABLE 26. FRANCE NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 27. FRANCE NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020-2030 ($MILLION)
TABLE 28. UK NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 29. UK NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020-2030 ($MILLION)
TABLE 30. ITALY NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 31. ITALY NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020-2030 ($MILLION)
TABLE 32. SPAIN NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 33. SPAIN NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020-2030 ($MILLION)
TABLE 34. REST OF EUROPE NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 35. REST OF EUROPE NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020-2030 ($MILLION)
TABLE 36. ASIA-PACIFIC NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 37. ASIA-PACIFIC NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020-2030 ($MILLION)
TABLE 38. ASIA-PACIFIC NARCOLEPSY DRUGS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 39. JAPAN NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 40. JAPAN NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020-2030 ($MILLION)
TABLE 41. CHINA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 42. CHINA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020-2030 ($MILLION)
TABLE 43. AUSTRALIA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 44. AUSTRALIA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020-2030 ($MILLION)
TABLE 45. INDIA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 46. INDIA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020-2030 ($MILLION)
TABLE 47. SOUTH KOREA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 48. SOUTH KOREA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020-2030 ($MILLION)
TABLE 49. REST OF ASIA-PACIFIC NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 50. REST OF ASIA-PACIFIC NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020-2030 ($MILLION)
TABLE 51. LAMEA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 52. LAMEA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020-2030 ($MILLION)
TABLE 53. LAMEA NARCOLEPSY DRUGS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 54. BRAZIL NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 55. BRAZIL NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020-2030 ($MILLION
TABLE 56. SAUDI ARABIA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 57. SAUDI ARABIA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2020-2030 ($MILLION)
TABLE 58. SOUTH AFRICA NARCOLEPSY DRUG MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 59. SOUTH AFRICA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC, 2020-2030 ($MILLION)
TABLE 60. REST OF LAMEA NARCOLEPSY DRUGS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 61. REST OF LAMEA NARCOLEPSY DRUGS MARKET, BY THERAPEUTICS, 2020-2030 ($MILLION)
TABLE 62. ARENA PHARMA: COMPANY SNAPSHOT
TABLE 63. ARENA PHARMA: OPERATING SEGMENTS
TABLE 64. ARENA PHARMA: PRODUCT PORTFOLIO
TABLE 65. BIOPROJET: COMPANY SNAPSHOT
TABLE 66. BIOPROJET: OPERATING SEGMENTS
TABLE 67. BIOPROJET: PRODUCT PORTFOLIO
TABLE 68. GRAYMARK HEALTHCARE: SNAPSHOT
TABLE 69. GRAYMARK HEALTHCARE: OPERATING SEGMENTS
TABLE 70. GRAYMARK HEALTHCARE: PRODUCT PORTFOLIO
TABLE 71. HIKMA: COMPANY SNAPSHOT
TABLE 72. HIKMA: OPERATING SEGMENTs
TABLE 73. HIKMA: PRODUCT PORTFOLIO
TABLE 74. JAZZ PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 75. JAZZ PHARMACEUTICALS: OPERATING SEGMENTS
TABLE 76. JAZZ PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 77. LIGAND PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 78. LIGAND PHARMACEUTICALS: OPERATING SEGMENTS
TABLE 79. LIGAND PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 80. SHIONOGI: COMPANY SNAPSHOT
TABLE 81. SHIONOGI: OPERATING SEGMENTS
TABLE 82. SHIONOGI: PRODUCT PORTFOLIO
TABLE 83. TAKEDA: COMPANY SNAPSHOT
TABLE 84. TAKEDA: OPERATING SEGMENTS
TABLE 85. TAKEDA: PRODUCT PORTFOLIO
TABLE 86. NOVARTIS: COMPANY SNAPSHOT
TABLE 87. NOVARTIS: OPERATING SEGMENTS
TABLE 88. NOVARTIS: PRODUCT PORTFOLIO
TABLE 89. TEVA: COMPANY SNAPSHOT
TABLE 90. TEVA: OPERATING SEGMENTS
TABLE 91. TEVA: PRODUCT PORTFOLIO
List of Figures
FIGURE 01. NARCOLEPSY DRUGS MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2018-2021
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2018-2021
FIGURE 06. MODERATE BARGAINING POWER OF BUYERS
FIGURE 07. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 08. LOW THREAT OF NEW ENTRANTS
FIGURE 09. LOW THREAT OF SUBSTITUTION
FIGURE 10. MODERATE COMPETITIVE RIVALRY
FIGURE 11. TOP PLAYER POSITIONING, 2020
FIGURE 12. DRIVERS, RESTRAINTS, AND OPPORTUNITY
FIGURE 13. NARCOLEPSY DRUGS MARKET FOR DAYTIME EXTREME SLEEPINESS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 14. NARCOLEPSY DRUGS MARKET FOR CATAPLEXIA, BY COUNTRY, 2020 & 2030 (%)
FIGURE 15. NARCOLEPSY DRUGS MARKET FOR OTHER DISEASE TYPE, BY COUNTRY, 2020 & 2030 (%)
FIGURE 16. NARCOLEPSY DRUGS MARKET FOR CENTRAL NERVOUS SYSTEM STIMULANTS, BY COUNTRY 2020 & 2030 (%)
FIGURE 17. NARCOLEPSY DRUGS MARKET FOR TRICYCLIC ANTIDEPRESSANTS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 18. NARCOLEPSY DRUGS MARKET FOR SODIUM OXYBATE, BY COUNTRY, 2020 & 2030 (%)
FIGURE 19. NARCOLEPSY DRUGS MARKET FOR SELECTIVE SEROTONIN REUPTAKE INHIBITOR, BY COUNTRY, 2020 & 2030 (%)
FIGURE 20. NARCOLEPSY DRUGS MARKET FOR OTHER THERAPEUTIC TYPE, BY COUNTRY, 2020 & 2030 (%)92
FIGURE 21. ARENA PHARMA: NET SALES, 2018-2020 ($MILLION)
FIGURE 22. HIKMA: NET SALES, 2018-2020 ($MILLION)
FIGURE 23. HIKMA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 24. HIKMA: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 25. JAZZ PHARMACEUTICALS: NET SALES, 2018-2020 ($MILLION)
FIGURE 26. JAZZ PHARMACEUTICALS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 27. LIGAND PHARMACEUTICALS: REVENUE, 2018-2020 ($MILLION)
FIGURE 28. LIGAND PHARMACEUTICALS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 29. SHIONOGI: REVENUE, 2018-2020 ($MILLION)
FIGURE 30. SHIONOGI: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 31. SHIONOGI: REVENUE SHARE BY GEOGRAPHY, 2020 (%)
FIGURE 32. TAKEDA: REVENUE, 2018-2020 ($MILLION)
FIGURE 33. TAKEDA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 34. TAKEDA: REVENUE SHARE BY GEOGRAPHY, 2020 (%)
FIGURE 35. NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 36. NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2020 (%)
FIGURE 37. TEVA: REVENUE, 2018-2020 ($MILLION)
FIGURE 38. TEVA: REVENUE SHARE BY SEGMENT, 2020 (%)

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...